Revolutionizing Cancer Treatment: Our Investment in Kernal Biologics, a Leader in the mRNA Space


Wally Wang

November 19, 2021

At SAV(Scale Asia Ventures), we are committed to identifying and supporting companies that leverage groundbreaking technology to create transformative solutions. We are proud to announce our investment in Kernal Biologics, a pioneering biotechnology company harnessing the power of machine learning to revolutionize cancer treatment.

Kernal Biologics, founded in 2016, is at the forefront of mRNA research and technology. By employing machine learning algorithms to analyze which proteins cancer ribosomes are more likely to produce and which they are less likely to produce, Kernal Biologics is developing cutting-edge mRNA therapeutics to target cancer cells more effectively and minimize harm to healthy cells.

Kernal Biologics' innovative technology combines the power of machine learning with the emerging field of mRNA therapeutics to create personalized cancer treatments. Key features of their technology include:

  1. Machine Learning Algorithms: Kernal Biologics uses advanced machine learning algorithms to analyze and predict the proteins produced by cancer ribosomes, enabling the development of highly targeted mRNA therapeutics.
  2. mRNA Therapeutics: Kernal Biologics' mRNA-based treatments are designed to specifically target cancer cells while sparing healthy cells, resulting in potentially more effective and safer cancer therapies.
  3. Personalized Medicine: By understanding the unique protein production profiles of individual cancer cells, Kernal Biologics is working towards creating personalized cancer treatments tailored to each patient's specific needs.

Kernal Biologics is a leader in the rapidly growing mRNA space, which has gained significant attention due to its potential to revolutionize cancer treatment and other areas of medicine. By leveraging machine learning to understand cancer ribosomes, Kernal Biologics is well-positioned to develop innovative mRNA therapeutics that could have a significant impact on the way cancer is treated in the future.

Kernal Biologics Enters Development Phase Reaching Critical Milestones for  its First mRNA-Based Cancer-Therapeutic Product

The global mRNA therapeutics market is projected to reach $7.4 billion by 2028, driven by the increasing prevalence of chronic diseases and the growing need for personalized medicine. Kernal Biologics' groundbreaking technology and leadership in the mRNA space position the company to capture a significant share of this expanding market.

We believe that Kernal Biologics is uniquely poised to revolutionize cancer treatment through its innovative technology and leadership in the mRNA space. Key reasons for our investment include:

  1. Groundbreaking Technology: Kernal Biologics combines the power of machine learning with the potential of mRNA therapeutics to create highly targeted and personalized cancer treatments.
  2. Leadership in the mRNA Space: Kernal Biologics is at the forefront of mRNA research and technology, positioning the company for success in the rapidly evolving biotechnology landscape.
  3. Experienced Team: The company's leadership and advisory team possess extensive expertise in biotechnology, machine learning, and drug development, equipping them to drive innovation and navigate the complex field of cancer therapeutics.
Scale Asia Ventures

At Scale Asia Ventures, we are excited to partner with Kernal Biologics as they continue to shape the future of cancer treatment and redefine the possibilities of mRNA therapeutics. By investing in this exceptional company, we are confident that we are supporting a transformative force in the biotechnology industry.

This may interest you